CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

Rhea-AI Summary

CNS Pharmaceuticals, a biopharmaceutical company focused on brain and central nervous system cancer treatments, announced that its CEO, John Climaco, will participate in a fireside chat at Alliance Global Partner's 2024 Healthcare Company Showcase.

The event is scheduled for May 21, 2024, at 1:40 PM ET and will be webcast live on the company's website.

Positive

• CNS Pharmaceuticals is actively participating in a prominent industry event, potentially increasing visibility and investor interest.
• The fireside chat by CEO John Climaco provides an opportunity to share company progress and future plans directly with investors.

Negative

• The press release lacks specific details about new product developments, financial performance, or clinical trial results, which could be important for investors.
• No new financial data or business developments were disclosed, limiting the immediate impact on stock performance.

Live webcast fireside chat on Tuesday, May 21^st at 1:40 PM ET

HOUSTON, TX / ACCESSWIRE / May 20, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET.

A live webcast of the event will be on the Events page of the Investors section of the Company's website (cnspharma.com).

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

When will CNS Pharmaceuticals present at the Alliance Global Partner's 2024 Healthcare Company Showcase?

CNS Pharmaceuticals will present on May 21, 2024, at 1:40 PM ET.

Who will represent CNS Pharmaceuticals at the Healthcare Company Showcase?

John Climaco, the CEO of CNS Pharmaceuticals, will represent the company.

Will the CNS Pharmaceuticals presentation at the Healthcare Company Showcase be available online?

Yes, the event will be webcast live on the Events page of the Investors section of CNS Pharmaceuticals' website.

What is the focus of CNS Pharmaceuticals?

CNS Pharmaceuticals specializes in developing novel treatments for primary and metastatic cancers in the brain and central nervous system.

What is the stock symbol for CNS Pharmaceuticals?

The stock symbol for CNS Pharmaceuticals is CNSP.